🚀 VC round data is live in beta, check it out!
Changchun BCHT Valuation Multiples
Discover revenue and EBITDA valuation multiples for Changchun BCHT and similar public comparables like Geron, Compass Therapeutics, TchaikaPharma, KalVista Pharmaceuticals and more.
Changchun BCHT Overview
About Changchun BCHT
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
Founded
2004
HQ
Employees
N/A
Website
Sectors
Financials (FY)
EV
$1B
Changchun BCHT Financials
Changchun BCHT reported last fiscal year revenue of $180M and EBITDA of $53M.
In the same fiscal year, Changchun BCHT generated $154M in gross profit, $53M in EBITDA, and $34M in net income.
Revenue (LTM)
Changchun BCHT P&L
In the most recent fiscal year, Changchun BCHT reported revenue of $180M and EBITDA of $53M.
Changchun BCHT expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $180M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $154M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 85% | XXX | XXX | XXX |
| EBITDA | — | XXX | $53M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 29% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 24% | XXX | XXX | XXX |
| Net Profit | — | XXX | $34M | XXX | XXX | XXX |
| Net Margin | — | XXX | 19% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Changchun BCHT Stock Performance
Changchun BCHT has current market cap of $1B, and enterprise value of $1B.
Market Cap Evolution
Changchun BCHT's stock price is $2.58.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1B | $1B | -2.0% | XXX | XXX | XXX | $0.08 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChangchun BCHT Valuation Multiples
Changchun BCHT trades at 6.0x EV/Revenue multiple, and 20.5x EV/EBITDA.
EV / Revenue (LTM)
Changchun BCHT Financial Valuation Multiples
As of April 18, 2026, Changchun BCHT has market cap of $1B and EV of $1B.
Equity research analysts estimate Changchun BCHT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Changchun BCHT has a P/E ratio of 31.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 6.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 20.5x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 24.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.1x | XXX | XXX | XXX |
| P/E | — | XXX | 31.4x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (54.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Changchun BCHT Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Changchun BCHT Margins & Growth Rates
Changchun BCHT's revenue in the last fiscal year declined by (33%).
Changchun BCHT Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (33%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (45%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Changchun BCHT Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Changchun BCHT | XXX | XXX | XXX | XXX | XXX | XXX |
| Geron | XXX | XXX | XXX | XXX | XXX | XXX |
| Compass Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| TchaikaPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| KalVista Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Annexon | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Changchun BCHT M&A Activity
Changchun BCHT acquired XXX companies to date.
Last acquisition by Changchun BCHT was on XXXXXXXX, XXXXX. Changchun BCHT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Changchun BCHT
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChangchun BCHT Investment Activity
Changchun BCHT invested in XXX companies to date.
Changchun BCHT made its latest investment on XXXXXXXX, XXXXX. Changchun BCHT invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Changchun BCHT
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Changchun BCHT
| When was Changchun BCHT founded? | Changchun BCHT was founded in 2004. |
| Where is Changchun BCHT headquartered? | Changchun BCHT is headquartered in China. |
| Is Changchun BCHT publicly listed? | Yes, Changchun BCHT is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Changchun BCHT? | Changchun BCHT trades under 688276 ticker. |
| When did Changchun BCHT go public? | Changchun BCHT went public in 2021. |
| Who are competitors of Changchun BCHT? | Changchun BCHT main competitors are Geron, Compass Therapeutics, TchaikaPharma, KalVista Pharmaceuticals. |
| What is the current market cap of Changchun BCHT? | Changchun BCHT's current market cap is $1B. |
| What is the current revenue of Changchun BCHT? | Changchun BCHT's last fiscal year revenue is $180M. |
| What is the current EV/Revenue multiple of Changchun BCHT? | Current revenue multiple of Changchun BCHT is 6.0x. |
| Is Changchun BCHT profitable? | No, Changchun BCHT is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.